STATE OF OXIDATIVE STRESS IN PATIENTS WITH COMBINED COURSE OF TYPE 2 DIABETES MELLITUS AND OSTEOPOROSIS

Abstract

Oxidative stress (OS) is one of the factors that can affect the development and progression of type 2 diabetes mellitus (DM) and osteoporosis (OP). In the literature, we did not find information about the state of the OS in patients with combined course of DM and OP.

The aim of the study – to investigate the state of oxidative stress in patients with a combined course of type 2 diabetes mellitus and osteoporosis.

Material and Methods. Study of 94 patients, among whom group 1 – 22 patients with osteoporosis (OP), group 2 – 22 patients with type 2 diabetes mellitus (DM), group 3 – 50 patients with combined course of these diseases. An ultrasound densitometry on an Omnisense 7000 ultrasound densitometer (BeamMedLtd, Israel) was performed for all patients. The bone tissue state was determined according to WHO criteria. The intensity of the OS was investigated by the level of nitrotyrosine in serum. Patients with type 2 DM were studied for glucose, HbA1c, insulin, and HOMA index.

Results. In patients with combined course of DM and OP, the severity of the OS increases, which is confirmed by a significant increase in the level of nitrotyrosine in 2.8 times compared with patients with isolated flow of OP and 2.1 times – with diabetes (p<0.05). The nitrotyrosine level had significant positive correlation with HbA1c (r= +0.29, p<0.05). Duration of DM more than 10 years is accompanied by an increase in the level of nitrotyrosine in 2.3 times compared with patients who have diabetes until 5 years old (p<0.05). The nitrotyrosine level had significant correlation with parameters ultrasound densitometry, which is confirmed by the negative correlation nitrotirosine and T-index of radial bone (r = -0.29, p <0.05), T-index of phalanx (r = -0.25, p <0.05).

Conclusions. In patients with combined course of DM and OP, there is an intensification of oxidative stress, which can be a manifestation of a "reciprocal encumbrance" syndrome. We can assume that along with standard therapy, these patients should receive antioxidant drugs.